Neomera develops non-addictive pain therapies for 1.5B+ chronic pain patients using a wet-lab biology platform that generates proprietary data, analyzed by custom AI to unlock undruggable targets, accelerate development 80%, and cut discovery costs 90%, backed by top accelerators and angel funding. Seed Funding opportunities open.